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Abstract
Methylglyoxal (MG) may be an important cause of diabetic complications. Its primary source is dihydroxyacetone phosphate (DHAP)
whose levels are partially controlled by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Using a human red blood cell (RBC) culture,
we examined the effect of modifying GAPDH activity on MG production. With the inhibitor koningic acid (KA), we showed a linear,
concentration-dependent GAPDH inhibition, with 5 AM KA leading to a 79% reduction of GAPDH activity and a sixfold increase in MG.
Changes in redox state produced by elevated pH also resulted in a 2.4-fold increase in MG production at pH 7.5 and a 13.4-fold increase at
pH 7.8. We found substantial inter-individual variation in DHAP and MG levels and an inverse relationship between GAPDH activity and
MG production (R= 0.57, P= 0.005) in type 2 diabetes. A similar relationship between GAPDH activity and MG was observed in vivo in
type 1 diabetes (R= 0.29, P= 0.0018).
Widely varying rates of progression of diabetic complications are seen among individuals. We postulate that modification of GAPDH by
environmental factors or genetic dysregulation and the resultant differences in MG production could at least partially account for this
observation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nonenzymatic glycation has been shown to play an
important role in the development of diabetic complications
[1]. One of the most powerful glycating agents is methyl-
glyoxal (MG), an alpha ketoaldehyde that is found at
elevated concentrations in diabetes. This compound is
extremely reactive as a glycating agent of proteins and other
important cellular components and has been shown to be
toxic to cultured cells [2–6]. In vivo, chronic oral admin-
istration of MG in mice induces renal damage [7]. Addi-
tional support for the role of MG in the development of
complications comes from studies demonstrating a protec-
tive effect for the guanidino compounds (aminoguanidine
and metformin) which have the ability to scavenge this
dicarbonyl [8–10]. Because of the toxic potential of MG
and its role as an important source of advanced glycation
end-products (AGEs), it is important to understand the
mechanisms that regulate its production in the disordered
metabolism associated with diabetes.
The production of MG occurs primarily from the triose-
phosphate (TP) intermediates in the glycolytic pathway,
which include dihydroxyacetone phosphate (DHAP) and
glyceraldehyde-3-phosphate (GAP) [11,12]. MG is pro-
duced by spontaneous nonenzymatic elimination of the
phosphate group or decomposition of the enediol intermedi-
ate at the active site of triose phosphate isomerase [13].
Other minor sources of MG include cytochrome P4502E1
catalyzed oxidation of acetone from ketone bodies, [2]
cleavage of Amadori products, [14] and catabolism of
threonine via aminoacetone [15].
Accumulation of TPs and the subsequent production of
MG can occur as a consequence of increased glycolytic
flux and/or a reduced ability of the glycolytic enzymes
downstream from TP to handle the increased flux. Of
particular importance is the enzyme responsible for the
metabolism of GAP, glyceraldehyde-3-phosphate dehydro-
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genase (GAPDH) [16], which catalyzes the reaction of
GAP to 1,3 diphosphoglycerate.
Recent evidence has suggested a variety of functions for
GAPDH, including a role in endocytosis, translational con-
trol of gene expression, nuclear tRNA export, DNA repli-
cation and repair as well as cell apoptosis [17]. Several other
seemingly unrelated functions have now been attributed to
this enzyme, including involvement in membrane fusion and
microtubule bundling [18]. In light of its many apparent
functions, perturbations in GAPDH have recently been
connected to cellular dysfunction in several neurodegener-
ative diseases [19–24].
The GAPDH gene has been sequenced and its structure
appears to be highly conserved throughout nature [25]. Only
one copy of the gene appears to be expressed, although recent
work in brain cells questions this assumption and suggests
the presence of heterogeneity in GAPDH [26]. Multiple
isoforms of GAPDH, probably due to posttranslational mo-
dification, are found in nature although their significance is
not clear.
The activity of GAPDH is exquisitely sensitive to mod-
ification by cellular processes that have been shown to be
significantly perturbed in diabetes. Since the enzyme con-
tains a highly reactive thiol at its active site (cysteine149)
[27], it is sensitive to modification by a variety of com-
pounds with subsequent loss of enzyme activity [28–30].
These compounds include reactive aldehydes [31–34],
glycating agents [35,36] and oxidative radicals [37]. Pseu-
dohypoxia secondary to excessive accumulation of L-lactate
from pyruvate in diabetes can result in a decreased ability to
generate NAD+, which in turn leads to impaired GAPDH
activity. Since GAPDH activity is dependent on regener-
ation of the oxidized form of this nucleotide, any factor that
produces elevated NADH/NAD+ ratios could have similar
effects [16,38].
Structural mutation of the GAPDH gene and altered gene
expression could lead to significantly altered function and
increased TP and MG production in response to hyper-
glycemia. GAPDH gene expression can be regulated by
hormonal, nutritional and metabolic factors, including insu-
lin, which can increase GAPDH mRNA and activity up to
10-fold in liver and fat cells. Mutations induced in the
promoter region of GAPDH can lead to altered regulation
of gene expression by nuclear transcription factors [39].
Circadian controller genes have also been shown to produce
cyclic regulation of GAPDH activity [40].
To our knowledge, there is currently very little informa-
tion concerning the activity of GAPDH as it relates to its
effects on MG production and potential complication out-
comes in diabetes. The work presented here will explore
some basic questions concerning these issues.
These studies examine the effect of the specific GAPDH
inhibitor, koningic acid (KA), as well as changes in redox
state and reduced glutathione (GSH) levels on the production
of triose phosphates and MG. We will also determine the
relationship of these same parameters to GAPDH activity
and MG production in red blood cells (RBCs) from patients
with type 2 diabetes with varying degrees of glycemic
control. Finally, we examined the relationship between
GAPDH activity and plasma MG levels in a large group of
patients with type 1 diabetes.
2. Materials and methods
2.1. Materials
All materials are from Sigma/Aldrich with the exception
of the following: 1,2-diamino-4,5-dimethoxybenzene
(DDB) (Toronto Research Chemicals), C18 solid phase
extraction cartridges (Phenomenex), diaphorase (ICN Bio-
medicals), Eagles Essential Vitamin Mix (Gibco/BRL). KA
was a gift from K Hasumi of Tokyo Noko University,
Tokyo, Japan.
2.1.1. Determination of reduced glutathione
A colorimetric DTNB-based GSH assay from Beutler et
al. [41] is used in the determination of RBC glutathione
levels.
2.1.2. Determination of GAPDH
Red cell GAPDH was determined spectrophotometrically
using the method of Byers [42].
2.1.3. Determination of DHAP
Red cell DHAP was determined spectrophotometrically
using the method of Michal and Beutler [43].
2.1.4. Determination of MG by HPLC
MG determinations by HPLC utilized a modification of
the procedure by Ohmori et al. [44]. The assay is based on
derivatization of MG and the internal standard 2-oxopenta-
noic acid with o-phenylenediamine (o-PDA), extraction and
quantitation by UV monitoring. In brief, the sample of media
or plasma is prepared for derivatization by perchloric acid
(PCA) precipitation with 0.075 ml of 60% PCA per milliliter
of sample. The PCA supernatant is treated with PDA and 2-
oxopentanoic acid internal standard to a final concentration
of 3.5 mM and 80 AM, respectively. Samples are incubated at
50 C for 1 h and subsequently brought to a pH of 2.5 with 1 N
KOH and extracted twice with ethyl ether. Due to the
volatility of the MG derivative, an aqueous phase is added
to the sample using 20 Al of 10 mM potassium phosphate pH
2.8 and mixed well. Samples are dried in a centrifugal eva-
porator until only the aqueous portion remains. The sample is
then brought to a volume of 50 Al with acetonitrile, and 20 Al
is injected for HPLC analysis.
Chromatography was performed using gradient elution
on a Prodigy 5 AM, ODS-3, 250 4.5-mm column. Solvent
A was 10 mM potassium phosphate, pH 2.8, and solvent B
was acetonitrile. Ultraviolet detection is at 316 nm. Quanti-
tation is performed against an internal standard based
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calibration curve. The lower limit of quantitation for a 1.5-
ml sample is 71 nM. In day coefficient of variation for 20
determinations was 6.4%.
2.1.5. Determination of MG by gas chromatography-mass
spectrometry (GC-MS)
The GC-MS assay was based on the method of McClel-
lan et al. [45] using DDB as the derivatizing agent. We have
modified the assay for GC-MS and have enhanced the
sensitivity and reliability of quantitation by using a C13
labeled MG internal standard. Following addition of 45 Al of
60% PCA on ice the sample is centrifuged at 18,000 g for
20 min; 225 Al of the supernatant is then mixed with 25 Al
of 10 mM DDB in duplicate, samples are incubated at 50 C
for 90 min and immediately adjusted to pH 2.3 with 0.5 M
dibasic sodium phosphate. This step is followed by solid
phase extraction utilizing 100 mg, C-18 cartridges that were
pretreated with 1-ml methanol and 1-ml water, followed by
1 ml of 20 mM ammonium phosphate pH 2.3. After loading,
the cartridge is washed twice with 1 ml of 20 mM ammo-
nium phosphate pH 2.3, and eluted with 1 ml of methanol.
The eluent was dried in a centrifugal evaporator until
approximately 50 Al of total volume remains. Ethyl acetate,
100 Al, was added to each tube and the samples were
centrifuged at 1000 g. The ethyl acetate supernatant was
used for GC-MS analysis.
Analysis was performed with a Shimadzu QP5050A GC/
MS equipped with an HP-1701, 0.25-Am film, 0.25-mm ID,
3-m capillary column. Carrier gas is helium with a split-less
injection mode, injector at 280 jC, and interface at 290 jC.
Sampling time is 1.5 min, followed by a temperature
program where column temperature was increased from
40 to 280 jC at 40j/min and held at 280 jC for 4 min.
The advanced flow control is used to maintain a constant
carrier gas flow. One-microliter samples are analyzed by
selective ion monitoring of the C12 and C13 MG derivative
6,7-dimethoxy-2-methylquinoxaline with target ions of
204.1, 189.1 and 161.1 for the C12 derivative and 207.1,
192.1 and 164.1 for the C13 derivative. Quantities were
determined by comparing to a known quantity of C13 MG
internal standard. For 0.6-ml plasma samples between day
coefficient of variation was 4% while the lower limit of
quantitation was 25 nM.
2.1.6. Determination of D-lactate by HPLC
We modified the assay of Ohmori and Iwamoto [46] and
improved its reproducibility while shortening the analysis
time by pre-treating the sample to remove endogenous
pyruvate by derivatization with PDA and removal with a
C18 resin. With endogenous pyruvate removed, the D-lactate
concentration is equivalent to the enzymatically derived
pyruvate.
Briefly, 1 ml of plasma or media samples is treated with 75
Al of 60% PCA, centrifuged, and the supernatant is treated
with 35 mM PDA for 2 h at 50 C to react with endogenous
pyruvate. Sample pH is adjusted to 6.0 with KOH, centri-
fuged and applied to a pre-equilibrated C-18 cartridge. The
eluent from the cartridge is used in the rest of the analysis. It
is added to a reaction mixture containing thioctamide,
diaphorase, NAD, hydrazine sulfate and D-lactate dehydro-
genase (D-LDH), and incubated at 37 C for 2 h. The 2-
ketobutyric acid internal standard is added at this point along
with PDA, and acidification with HCl. Samples are incu-
bated 1 h at 50 C. After the pH is adjusted to 3.0 with sodium
phosphate dibasic they are extracted with 1 ml of ethyl
acetate. Samples are taken to dryness in a centrifugal
evaporator and reconstituted with 125 Al of HPLC buffer.
Twenty microliters of sample was used in the analysis.
Chromatography was performed on a Phenomenex Prod-
igy, 5 AM, C-18, 4.6 250-mm column. Samples were
eluted isocratically with 75% 10 mM potassium phosphate
pH 2.9 and 25% acetonitrile. Ultraviolet detection was at
334 nM. Between day coefficient of variation for media was
9% with a lower limit of detection of 4.0 AM.
2.1.7. RBC culture conditions
RBCs were cultured according to the culture system
developed by Freedman [47]. Media consisted of Earle’s
salts with 18 mM HEPES and 25 mM sodium bicarbonate
supplemented with Eagle’s Essential Vitamin Mix, 1% BSA,
L-cysteine, L-glutamine, L-glutamic acid, glycine and genta-
mycin sulfate. Cells were incubated at 37 jC and 5% CO2 in
25-cm2 tissue culture flasks. In our experiments strict control
of media pH was essential for reproducible results in the
system.
2.1.8. RBC culture
Blood was collected in the fasting state into EDTA
vacutainer tubes and immediately placed on ice. Samples
were centrifuged and RBCs were separated from the plasma
and buffy coat. RBCs were cultured for 2.5–3 days with a
5% hematocrit. In order to stabilize pH, media was pre-
incubated overnight at 5% CO2 prior to the addition of cells.
Cells were then added and incubated overnight with 5 mM
glucose before increasing the glucose concentration to 30
mM. At time zero, 25 mM glucose was added to the cells and
one half of the media and cell suspension were removed as a
zero-time sample. After 32 or 48 h of incubation the
remaining cells were harvested and processed. Cells were
pelleted and snap-frozen and media was frozen for later
analysis. Typically, red cells were analyzed for MG, GAPDH
activity and GSH. Media was analyzed for MG and DL.
When the above analyses were performed in six separate
cell cultures utilizing RBCs from the same subject, the
following coefficients of variation were achieved for each
parameter at the 48-h time point: Media MG= 12%, media
DL= 9%, GSH= 10% and GAPDH= 7%.
2.1.9. Effect of pH on media MG
RBCs from normal donors were isolated and cultured for
24 h in EBSS with 30 mM glucose and varying sodium
bicarbonate concentrations designed to produce a range of
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pH from 7.1 to 7.8 in a 5% CO2 environment. Media MG
levels were determined by HPLC.
2.1.10. Incubations with KA
Normal RBCs were isolated, washed with EBSS and
treated for 1 h with KA. The cells were washed twice and
placed into the usual culture conditions. The effect of KA on
the activity of GAPDH, the concentration of GSH and the
production of MG and DL were evaluated after 48-h
exposure to 30 mM glucose.
2.2. Diabetic study populations
The first population was made up of 20 subjects with
type 2 diabetes being treated with varying combinations of
oral agents and insulin. All subjects had normal renal
function with a mean creatinine clearance of 110 ml/min.
The mean HbA1c was 7.9% and the mean age was 64 years.
There were equal numbers of males and females and the
mean duration of diabetes was 15 years.
The second population consisted of 110 subjects with type
1 diabetes participating in ‘‘The Natural History of Diabetic
Nephropathy Study’’ [48]. The mean age was 22.3F 7 years
and the mean duration of diabetes was 12.3F 4.1 years. All
subjects had normal renal function with mean GFR (iotha-
lamate clearance) of 131F 26 ml/min.
We also studied 29 non-diabetic controls with a mean age
of 41.1F13.8 years.
3. Results
3.1. Inhibition of GAPDH by KA
Since KA is a potent and specific inhibitor of GAPDH
[49] we took advantage of this effect to determine the
relationship between the level of GAPDH inhibition and
production of MG in our cell culture system. As shown in
Fig. 1A, there is an inverse linear relationship between
GAPDH activity and KA concentration with a detectable
decrease of GAPDH activity at 2 AM and a decrease to 21%
of control at 5 AM KA. Production of both MG and D-lactate
were significantly enhanced at 48 h in a nonlinear dose
response (Fig. 1B) with a sixfold increase in MG and a
fourfold increase in DL over control levels. This effect did
not appear to be secondary to changes in oxidative stress
since GSH levels were minimally effected by 5 AM KA
(Fig. 1B). An increase in the abundance of MG relative to
DL was observed after exposure to KA, with the MG/DL
ratio (pmol/nmol) increasing from 0.278 in control cells to
0.454 in cells treated with 5 AM KA.
3.2. Effect of pH on GAPDH activity and MG production
The NADH/NAD ratio of the cell is an important mod-
ulator of GAPDH activity [16]. Since alterations in pH can
influence the NADH/NAD ratio and inhibit GAPDH, we
cultured normal RBCs with modified sodium bicarbonate
levels resulting in precise changes in pH. As shown in Fig. 2,
increasing pH dramatically increased media MG concentra-
tions, with a sharp 2.4-fold increase occurring as pH rises
just above the physiological range (pH = 7.5), and 13.4-fold
increase at pH 7.8. DL levels were also measured and
followed a nearly identical pattern. Concurrently we
observed a decrease in media pyruvate from 80 AM at pH
7.4 to 15 AM at pH 7.8, indicating an altered L-lactate-to-
pyruvate ratio.
Fig. 1. (A) Inhibition of GAPDH enzyme activity by koningic acid. RBCs
from a normal donor were isolated, washed with Earle’s Balanced Salts and
treated for 1 h with the indicated concentrations of KA. The cells were
again washed twice and placed into the usual culture conditions described
in Materials and methods and incubated for 48 h. Each point represents
duplicate analysis of GAPDH activity for individual flasks. Line statistics:
y= 11.922x + 74.797, R2 = 0.9828. (B) Effect of koningic acid on MG,
DL, and GSH levels. Using RBCs treated as in 1A, media MG and DL
levels and intracellular GSH levels were determined and expressed as
percent of control levels. Each point represents the mean of two flasks.
Chart symbols: (x) methylglyoxal, (n) D-lactate, (E) GSH.
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3.3. GAPDH activity and MG levels in type 2 diabetes
To study the effect of variation in GAPDH activity on MG
levels in diabetic patients we utilized freshly harvested RBCs
in our culture system. Cells obtained from type 2 diabetic
subjects exhibited wide variation in intracellular DHAP and
MG levels when exposed to 30 mM glucose for 32 h. DHAP
levels ranged from 28 to 195 nM/g protein and MG levels
from 900 to 2100 pM/g protein (Fig. 3). However, we
observed no correlation between the preceding level of
glycemic control as measured by HbA1c and the production
of MG and DL in culture. GAPDH activity in these cells
showed a significant negative correlation (P= 0.005) with
MG concentration at 32 h (Fig. 4A). GAPDH activity at zero
hour (prior to the 32-h incubation with 30 mM glucose) also
showed a significant inverse correlation with MG (P= 0.016,
R = 0.5, data not shown). As expected, intracellular DHAP
levels showed a significant positive correlation with produc-
tion of MG, (Fig. 4B).
3.4. MG production and GAPDH activity and diabetic
complications
We observed a significant increase in mean MG produc-
tion in cultured RBCs from the small number of subjects
with type 2 diabetes and proliferative retinopathy (N = 4)
compared to no retinopathy (N = 9) (P= 0.02 by ANOVA).
Fig. 2. Effect of pH on media MG. RBCs from a normal donor were
isolated and cultured for 24 h in EBSS with 30 mM glucose and varying
sodium bicarbonate concentrations designed to produce a range of pHs
from 7.1 to 7.8 in a 5% CO2 environment. Media MG levels were
determined. Each point represents the mean of three individual flasks.
Fig. 3. Variable generations of MG from hyperglycemia. RBCs from
patients with type 2 diabetes were cultured for 32 h under conditions
described in Materials and methods. Subjects showed widely divergent
increases in intracellular levels of MG from 900 to 2100 pmol of MG per
gram of protein.
Fig. 4. (A) GAPDH activity determines methylglyoxal levels. RBCs from
patients with type 2 diabetes were cultured for 32 h under conditions
described in Materials and methods. Intracellular MG and DHAP levels and
GAPDH activity were measured in the RBCs. A significant inverse
correlation is seen between GAPDH activity and MG levels ( P= 0.005,
R = 0.57). (B) Intracellular DHAP concentrations determine methylglyoxal
levels. A significant correlation is seen between DHAP concentrations and
MG levels ( P= 0.04, R= 0.45).
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We also found that GAPDH activity in RBCs from patients
with evidence of coronary artery disease tended to be lower
than in patients with no history of disease although sig-
nificance at the P < 0.05 level was not quite achieved
(P= 0.069).
3.5. GAPDH activity and MG levels in type 1 diabetes
To further characterize GAPDH activity in the clinical
setting we measured plasma MG and glucose levels, and
RBC GAPDH activity in 110 subjects with type 1 diabetes
and in 29 non-diabetic controls. To adjust for the effect of
plasma glucose on MG we expressed MG production per
millimolar of glucose. This combined population regression
analysis showed a significant negative correlation between
GAPDH activity and the ratio of MG/glucose (P= 0.0018,
R = 0.29) (Fig. 5). These results suggest a measurable
in vivo relationship between GAPDH enzyme activity in
RBCs and the rate of production of MG from glucose.
4. Discussion
Since methyglyoxal is a potent glycating agent associated
with diabetic complications [2,50–52], detailed knowledge
of the biology of production and detoxification of this
compound is essential to understanding its role in diabetes,
aging and other diseases.
GAPDH controls a crucial metabolic step that determines
the levels of MG precursors and can therefore regulate its
production [11]. To study the effect of GAPDH inhibition
we utilized a RBC culture system and demonstrated that
inhibition by KA predictably increases media MG and DL
concentrations (Fig. 1A and B). Detectable increases in MG
accumulation were seen at 30% inhibition of enzyme
activity while 79% inhibition led to a sixfold increase in
MG production. Intracellular GSH, an important indicator of
cellular health and oxidative stress, did not show significant
change supporting a direct effect for KA on GAPDH
activity (Fig. 1B). The observed increase in MG relative
to DL in cells exposed to 5 AM KA could be attributed to a
decrease in the efficiency of MG detoxification by the GSH-
dependent glyoxylase system. We did observe a small
decrease in GSH concentration after 5 AM KA treatment
but it is not clear if this or other factors influence the con-
version of MG to DL.
Since KA appears to have specificity for certain S-loop
configurations, and the sequence of the S-loop in the
enzyme can be crucial to inhibitor action [49], the literature
was examined for its potential interaction with other impor-
tant enzymes in the glycolytic pathway. In the initial work
done on KA it was not found to inhibit triosephosphate
isomerase or phosphoglycerate kinase [53]. G6PD does not
have an active site susceptible to attack [54] and LDH has
no potential sites suitable for modification by KA. The
enzyme one step downstream from GAPDH, phosphogly-
ceromutase, does have a Cys residue that could effect
catalytic activity. This residue is outside the active site of
the enzyme, however, and no data is available for the effect
of KA on its activity [55].
Metabolic perturbations of the cell redox state can also
influence GAPDH activity and the accumulation of MG
[16]. We have validated this in our RBC incubation system
by showing that a modest increase to pH 7.5 leads to a
substantial 2.4-fold accumulation of MG while more dra-
matic 13.4-fold increases in MG production are seen as pH
approaches 7.8 (Fig. 2). Increasing pH was associated with
significant decreases in intracellular pyruvate levels, sug-
gesting that changes in L-lactate-to-pyruvate ratio may be at
least partially responsible for the observed increases in MG.
These observations also suggest that episodes of mild
alkalosis could lead to burst of increased MG production
in the clinical setting.
Our data characterize the in vitro production of MG and
DL after GAPDH inhibition by chemical modification or by
modification of the NAD/NADH ratio. Both results confirm
the predicted accumulation of MG and document the ability
of our cell culture system to quantify the relationship
between GAPDH activity and the subsequent accumulation
of metabolites.
When RBCs from diabetic subjects were cultured under
hyperglycemic conditions we saw wide individual variation
in production of MG and DL (Fig. 3). There was no
correlation between the preceding level of glycemic control
as measured by HbA1c and the production of MG and DL in
culture. MG and DL production increased with declining
GAPDH activity and were directly related to the intra-
cellular levels of DHAP, indicating the physiologic impor-
tance of GAPDH activity on ambient MG levels (Fig. 4A
and B). In a large sample of type 1 diabetics and non-
Fig. 5. GAPDH activity correlates negatively with MG production. RBC
GAPDH activity, plasma MG levels, and plasma glucose levels were
determined in a group of 84 patients with type 1 diabetes and 29 non-
diabetic controls. MG is expressed as MG concentration in nanomolar
divided by plasma glucose levels in millimolar to correct MG levels for the
ambient glucose concentration. Regression analysis reveals a significant
negative correlation ( P= 0.0018, R = 0.291) between GAPDH activity and
corrected MG levels.
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diabetic controls, the amount of MG corrected for glucose
concentration was inversely correlated with GAPDH activ-
ity (Fig. 5). This data again demonstrates the biological
relevance of GAPDH regulation in vivo, and suggests that
individual variations in GAPDH activity could lead to
variable MG production on exposure to hyperglycemia.
In diabetes, elevated glucose concentration is an impor-
tant factor in determining the appearance of diabetic com-
plications [56]. The direct effects of glucose have been
extensively studied, and have been shown to produce
secondary metabolic changes that may have important
implications for the ultimate appearance of complications.
We believe that increased production of MG is one of the
most important of these secondary effects.
The majority of published studies have demonstrated that
diabetes-related hyperglycemia is associated with elevated
levels (3–10 fold) of intracellular TPs (GAP and DHAP) in
cardiac muscle [57], RBCs [58] and lens [59,60], although
two other studies did not confirm these findings [61,62].
This accumulation of TPs and the subsequent production of
MG could be a consequence of increased glycolytic flux
and/or a reduced ability of the glycolytic enzymes down-
stream from TP to handle the increased flux. In all of the
studies reported above, diabetes-related increased glycolytic
flux was supported by the consistent elevation of glucose-6-
phosphate and fructose-6-phosphate levels. Our observa-
tions of diabetes-related reductions in GAPDH activity
supports a role for this enzyme in greater MG production.
Since GAPDH plays a significant regulatory role in
the production of MG, it is important to understand the
mechanisms by which hyperglycemia can regulate
GAPDH activity. It has been shown that its activity is
readily influenced by oxidative stress [63–65], direct
glycation by glucose [35] or modification by MG [32],
as well as changes in the NAD/NADH ratio [16]. Fig. 6
illustrates the major metabolic pathways that influence
MG production and points out the possible mechanisms
by which diabetes-related hyperglycemia might influence
the activity of GAPDH. One possible mechanism is the
increased flux through the sorbitol pathway produced by
elevated glucose levels [66]. Since the conversion of
sorbitol to fructose requires NAD, this increased flux
would reduce the amount of this nucleotide available for
GAPDH activity, leading to GAPDH inhibition and
enhanced production of MG [16]. Increased polyol flux
also produces a greater demand for NADPH during the
conversion of glucose to sorbitol, thus competing for
NADPH in the hexose monophosphate shunt and ulti-
mately reducing regeneration of GSH from GSSG [66].
Depletion of GSH through this mechanism could
adversely effect the cell by inhibiting the GSH-dependent
glyoxylase system, or by lowering the cellular GSH
related antioxidant defenses leading to oxidative modifi-
cation and inactivation of GAPDH [49,67]. Increased
glucose concentration can also enhance oxidative stress
though the production of glycation-derived free radicals
Fig. 6. Major metabolic pathways influencing methylglyoxal production.
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that in turn can produce reactive aldehydes and ketones
from lipid substrates [31,63,66]. One possible mechanism
for this has been proposed by Nishikawa et al. [64] who
hypothesize that elevated glucose can alter mitochondrial
metabolism thus enhancing the production of reactive
superoxide. This in turn impacts the activity of protein
kinase C, aldose reductase, and increases MG production
via GAPDH inhibition [6,68]. All of these studies show
that regulation of GAPDH by environmental factors has
the potential to be an important independent modifier of
MG levels and potentially of diabetic complications.
GAPDH has traditionally been considered to be a con-
stitutive ‘‘housekeeping’’ enzyme, but recent studies have
documented a variety of novel functions for this protein
including a role in endocytosis, the translational control of
gene expression, nuclear tRNA export, DNA replication
and repair as well as cell apoptosis [17]. GAPDH inhibition
has been implicated as a potential factor in the pathogenesis
of several inherited degenerative neuorological diseases,
[20–22]. The mechanism of tissue damage is not clear
but one possibility is that cell toxicity via GAPDH inhib-
ition and overproduction of MG could play a role. Ameli-
oration of neurotoxicity by MG inactivating agents such as
metformin, aminoquanidine and carnosine also supports
this hypothesis [69–71]. Decreased GAPDH activity may
also play a role in the high rates of atherosclerosis asso-
ciated with diabetes and the insulin resistance syndrome
[72]. Based on the data presented in this manuscript and the
diverse studies implicating the role of GAPDH in the
pathogenesis of vascular and neural damage, we propose
that excess MG production may be at least partially
responsible for some of the observed toxic effects seen
with GAPDH inhibition. We are currently investigating the
possible role of GAPDH in diabetic complications and are
exploring more detailed mechanisms of GAPDH inhibition
using molecular techniques.
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